by Clinical Neuropsychologist | Thursday, March 20, 2025 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is characterized by amyloid pathology and neuroinflammation, leading to cognitive decline. Targeting histone deacetylase-11 (HDAC11) offers a novel therapeutic strategy due to its role in immune regulation. METHODS...
by Clinical Neuropsychologist | Thursday, March 20, 2025 | Dementia
Abstract Interventions addressing modifiable personal and environmental factors are critical to optimize dementia mealtime care, caregiving, and outcomes. This review synthesized the characteristics and effects of non-pharmacological interventions on mealtime care and...
by Clinical Neuropsychologist | Thursday, March 20, 2025 | Dementia
Abstract INTRODUCTION Plasma biomarkers sensitive to Alzheimer’s disease (AD) proteinopathy prior to the onset of dementia have significant implications for early detection. METHODS In 304 individuals without dementia, we investigated whether C2N Diagnostics’...
by Clinical Neuropsychologist | Friday, March 14, 2025 | Dementia
Abstract INTRODUCTION Digital voice analysis is an emerging tool for differentiating cognitive states, but it poses privacy risks as automated systems may inadvertently identify speakers. METHODS We developed a computational framework to evaluate the trade-off between...
by Clinical Neuropsychologist | Friday, March 7, 2025 | Dementia
Abstract INTRODUCTION The ability to integrate information across sensory modalities is a vital aspect of everyday functioning and is linked to cognition. Increasing evidence suggests that Alzheimer’s disease (AD) pathology manifests in sensory association areas...
by Clinical Neuropsychologist | Thursday, March 6, 2025 | Dementia
Abstract INTRODUCTION Amyloid beta oligomers (Aβos) are toxic to synapses and key to the progression of Alzheimer’s disease (AD) and amyloid pathology, representing a target for therapeutic strategies. METHODS Amyloid and small ubiquitin modifier 2 (SUMO2)...
